User login
Pediatric Dermatology Consult - April 2016
By Catalina Matiz, M.D., and David Ginsberg
Eczema cocksackium
Eczema coxsackium (EC) is an atypical variant of hand, foot, and mouth disease (HFMD) that occurs in patients with atopic dermatitis lesions. HFMD is a common viral exanthema seen in pediatric populations, predominantly in children under 5 years of age, and is most commonly caused by coxsackievirus A16 in the United States.1-3 Enterovirus 71 is also a common cause of HFMD in Asian countries, and in rare cases has been linked to more severe neurologic manifestations.2,3
Over the past several years, infection by coxsackievirus A6 (CVA6) has been responsible for HFMD outbreaks in multiple countries around the globe.1-5 This particular strain of coxsackievirus is known for causing atypical HFMD, which has several overlapping variations. The variants of atypical HFMD caused by CVA6 include eczema coxsackium (EC), widespread vesiculobullous and erosive lesions, purpuric lesions, and Gianotti-Crosti-like eruptions.2 EC is the result of a CVA6 infection in a child with a history of atopic dermatitis (AD). The infection in these patients is a more severe form of HFMD, presenting with eczema herpeticum (EH)-like lesions, with some combination of vesicles, papules, and erosions, in areas affected by atopic dermatitis.2,3 This is in contrast to classic HFMD, which commonly presents with oral erosions, and small vesicles limited to the hands, feet, and buttocks.1,2
In addition to the dermatologic manifestations, patients with EC also can present with other symptoms including fever and oropharyngeal pain.2,3 Any of the variants of atypical HFMD can present with lesions, including erosions, vesicles, and bullae, in areas of skin irritation such as sunburns, irritant dermatitis, lacerations, and tinea pedis.2
Differential diagnosis
The differential diagnosis for EC includes EH, impetiginized atopic dermatitis, varicella, and erythema multiforme major.2-4 EH is typically the highest on the differential because the presentation of EC is described as an EH-like rash and on occasion it is difficult to differentiate the two.2 When diagnosing EC, the history plays an important role, and it is imperative to question whether the patient has come into contact with anyone with cold sores to help rule out EH. It is recommended to perform testing for herpes simplex virus (HSV), either by culture, polymerase chain reaction (PCR), or direct immunofluorescence if the diagnosis is not straightforward.2,5 To confirm the diagnosis of EC, CVA6 PCR can be performed.4 The ideal sample would be from vesicular fluid because the same sample also could be used to test for HSV to help rule out EH, but throat swabs and stool samples also can be used.2 As lesions in EH can sometimes be superinfected with bacteria such as Staphylococcus aureus or streptococcus, a bacterial swab for culture and sensitivities is also recommended prior to starting empiric antimicrobial therapy.
Treatment
Because EC was only characterized several years ago, and the majority of the cases reported have been self-limiting, there has been little research done looking into the best treatment. The majority of the literature recommends treating symptomatically in a similar fashion to an eczema flare including daily moisturizing, bleach baths, and topical corticosteroids as needed.6 There has been a report that using wet wraps with lower-strength corticosteroids is an effective treatment method for severe cases.6 Treatment with acyclovir and oral antimicrobials is recommended if the diagnosis of EH is in question and HSV and bacterial testing are pending.
References
- JAMA. 2012;308(4):335.
- Pediatrics. 2013 Jul;132(1):e149-57.
- PIDJ. 2014 Apr;33(4):e92-98.
- Virol J. 2013 Jun 24;10:209.
- Lancet Infect Dis. 2014 Jan;14(1):83-6.
- J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):803-4.
Dr. Matiz is assistant professor of dermatology at Rady Children’s Hospital San Diego–University of California, San Diego and Mr. Ginsberg is a research associate at the hospital. Dr. Matiz and Mr. Ginsberg said they have no relevant financial disclosures.
By Catalina Matiz, M.D., and David Ginsberg
Eczema cocksackium
Eczema coxsackium (EC) is an atypical variant of hand, foot, and mouth disease (HFMD) that occurs in patients with atopic dermatitis lesions. HFMD is a common viral exanthema seen in pediatric populations, predominantly in children under 5 years of age, and is most commonly caused by coxsackievirus A16 in the United States.1-3 Enterovirus 71 is also a common cause of HFMD in Asian countries, and in rare cases has been linked to more severe neurologic manifestations.2,3
Over the past several years, infection by coxsackievirus A6 (CVA6) has been responsible for HFMD outbreaks in multiple countries around the globe.1-5 This particular strain of coxsackievirus is known for causing atypical HFMD, which has several overlapping variations. The variants of atypical HFMD caused by CVA6 include eczema coxsackium (EC), widespread vesiculobullous and erosive lesions, purpuric lesions, and Gianotti-Crosti-like eruptions.2 EC is the result of a CVA6 infection in a child with a history of atopic dermatitis (AD). The infection in these patients is a more severe form of HFMD, presenting with eczema herpeticum (EH)-like lesions, with some combination of vesicles, papules, and erosions, in areas affected by atopic dermatitis.2,3 This is in contrast to classic HFMD, which commonly presents with oral erosions, and small vesicles limited to the hands, feet, and buttocks.1,2
In addition to the dermatologic manifestations, patients with EC also can present with other symptoms including fever and oropharyngeal pain.2,3 Any of the variants of atypical HFMD can present with lesions, including erosions, vesicles, and bullae, in areas of skin irritation such as sunburns, irritant dermatitis, lacerations, and tinea pedis.2
Differential diagnosis
The differential diagnosis for EC includes EH, impetiginized atopic dermatitis, varicella, and erythema multiforme major.2-4 EH is typically the highest on the differential because the presentation of EC is described as an EH-like rash and on occasion it is difficult to differentiate the two.2 When diagnosing EC, the history plays an important role, and it is imperative to question whether the patient has come into contact with anyone with cold sores to help rule out EH. It is recommended to perform testing for herpes simplex virus (HSV), either by culture, polymerase chain reaction (PCR), or direct immunofluorescence if the diagnosis is not straightforward.2,5 To confirm the diagnosis of EC, CVA6 PCR can be performed.4 The ideal sample would be from vesicular fluid because the same sample also could be used to test for HSV to help rule out EH, but throat swabs and stool samples also can be used.2 As lesions in EH can sometimes be superinfected with bacteria such as Staphylococcus aureus or streptococcus, a bacterial swab for culture and sensitivities is also recommended prior to starting empiric antimicrobial therapy.
Treatment
Because EC was only characterized several years ago, and the majority of the cases reported have been self-limiting, there has been little research done looking into the best treatment. The majority of the literature recommends treating symptomatically in a similar fashion to an eczema flare including daily moisturizing, bleach baths, and topical corticosteroids as needed.6 There has been a report that using wet wraps with lower-strength corticosteroids is an effective treatment method for severe cases.6 Treatment with acyclovir and oral antimicrobials is recommended if the diagnosis of EH is in question and HSV and bacterial testing are pending.
References
- JAMA. 2012;308(4):335.
- Pediatrics. 2013 Jul;132(1):e149-57.
- PIDJ. 2014 Apr;33(4):e92-98.
- Virol J. 2013 Jun 24;10:209.
- Lancet Infect Dis. 2014 Jan;14(1):83-6.
- J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):803-4.
Dr. Matiz is assistant professor of dermatology at Rady Children’s Hospital San Diego–University of California, San Diego and Mr. Ginsberg is a research associate at the hospital. Dr. Matiz and Mr. Ginsberg said they have no relevant financial disclosures.
By Catalina Matiz, M.D., and David Ginsberg
Eczema cocksackium
Eczema coxsackium (EC) is an atypical variant of hand, foot, and mouth disease (HFMD) that occurs in patients with atopic dermatitis lesions. HFMD is a common viral exanthema seen in pediatric populations, predominantly in children under 5 years of age, and is most commonly caused by coxsackievirus A16 in the United States.1-3 Enterovirus 71 is also a common cause of HFMD in Asian countries, and in rare cases has been linked to more severe neurologic manifestations.2,3
Over the past several years, infection by coxsackievirus A6 (CVA6) has been responsible for HFMD outbreaks in multiple countries around the globe.1-5 This particular strain of coxsackievirus is known for causing atypical HFMD, which has several overlapping variations. The variants of atypical HFMD caused by CVA6 include eczema coxsackium (EC), widespread vesiculobullous and erosive lesions, purpuric lesions, and Gianotti-Crosti-like eruptions.2 EC is the result of a CVA6 infection in a child with a history of atopic dermatitis (AD). The infection in these patients is a more severe form of HFMD, presenting with eczema herpeticum (EH)-like lesions, with some combination of vesicles, papules, and erosions, in areas affected by atopic dermatitis.2,3 This is in contrast to classic HFMD, which commonly presents with oral erosions, and small vesicles limited to the hands, feet, and buttocks.1,2
In addition to the dermatologic manifestations, patients with EC also can present with other symptoms including fever and oropharyngeal pain.2,3 Any of the variants of atypical HFMD can present with lesions, including erosions, vesicles, and bullae, in areas of skin irritation such as sunburns, irritant dermatitis, lacerations, and tinea pedis.2
Differential diagnosis
The differential diagnosis for EC includes EH, impetiginized atopic dermatitis, varicella, and erythema multiforme major.2-4 EH is typically the highest on the differential because the presentation of EC is described as an EH-like rash and on occasion it is difficult to differentiate the two.2 When diagnosing EC, the history plays an important role, and it is imperative to question whether the patient has come into contact with anyone with cold sores to help rule out EH. It is recommended to perform testing for herpes simplex virus (HSV), either by culture, polymerase chain reaction (PCR), or direct immunofluorescence if the diagnosis is not straightforward.2,5 To confirm the diagnosis of EC, CVA6 PCR can be performed.4 The ideal sample would be from vesicular fluid because the same sample also could be used to test for HSV to help rule out EH, but throat swabs and stool samples also can be used.2 As lesions in EH can sometimes be superinfected with bacteria such as Staphylococcus aureus or streptococcus, a bacterial swab for culture and sensitivities is also recommended prior to starting empiric antimicrobial therapy.
Treatment
Because EC was only characterized several years ago, and the majority of the cases reported have been self-limiting, there has been little research done looking into the best treatment. The majority of the literature recommends treating symptomatically in a similar fashion to an eczema flare including daily moisturizing, bleach baths, and topical corticosteroids as needed.6 There has been a report that using wet wraps with lower-strength corticosteroids is an effective treatment method for severe cases.6 Treatment with acyclovir and oral antimicrobials is recommended if the diagnosis of EH is in question and HSV and bacterial testing are pending.
References
- JAMA. 2012;308(4):335.
- Pediatrics. 2013 Jul;132(1):e149-57.
- PIDJ. 2014 Apr;33(4):e92-98.
- Virol J. 2013 Jun 24;10:209.
- Lancet Infect Dis. 2014 Jan;14(1):83-6.
- J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):803-4.
Dr. Matiz is assistant professor of dermatology at Rady Children’s Hospital San Diego–University of California, San Diego and Mr. Ginsberg is a research associate at the hospital. Dr. Matiz and Mr. Ginsberg said they have no relevant financial disclosures.
A 16-month-old male with a history of mild atopic dermatitis presents with a 2-day history of a rash on his lower extremities, arms, abdomen, and face. His father reports that it began as a single spot on his leg and has spread over the past 2 days. His other symptoms included a fever of 101.5 F, hypoactivity, and an unwillingness to eat solid foods. The patient has not had contact with anyone with cold sores. The sister is developing similar lesions on her face and knees. Physical exam On exam there are hemorrhagic crusted papules with an erythematous base, as well as grouped vesicles and eroded punched-out papules scattered on the lower extremities bilaterally. The area of involvement extends from his ankles to his hips, involving the posterior thighs, inguinal folds, and calves. There also are some hemorrhagic crusted erythematous grouped papules scattered on the upper extremities. On the face there are few crusted erythematous papules around the mouth. On the soles there are few erythematous oval papules.
AATS Graham Foundation Programs Open with July Deadlines
Two AATS Graham Foundation programs are now open for application.
Third John Alexander Research Scholarship provides research, training and experience for North American surgeons committed to pursuing an academic career in cardiothoracic surgery. This two-year scholarship will run from July 1, 2017 - June 30, 2019 and provides an annual $80,000 stipend to the host institution.
* Applications must be submitted during the candidate’s first two years in an academic position.
* Research must occur within the first three years after completion of an approved North American cardiothoracic residency.
Deadline: July 1, 2016
Evarts A. Graham Memorial Traveling Fellowship supports training of international surgeons with the potential for future thoracic surgical leadership. The fellowship will run from 2017-2018 and provide a stipend of $75,000 to help cover living and travel expenses for fellows while visiting North American medical centers.
* Candidates must be from other than North America, who have not limited (six months or less) clinical training in North American prior to submitting their application.
* Candidates must have completed their formal training in general and thoracic/cardiovascular surgery but not yet reached a senior position.
Deadline: July 1, 2016
Two AATS Graham Foundation programs are now open for application.
Third John Alexander Research Scholarship provides research, training and experience for North American surgeons committed to pursuing an academic career in cardiothoracic surgery. This two-year scholarship will run from July 1, 2017 - June 30, 2019 and provides an annual $80,000 stipend to the host institution.
* Applications must be submitted during the candidate’s first two years in an academic position.
* Research must occur within the first three years after completion of an approved North American cardiothoracic residency.
Deadline: July 1, 2016
Evarts A. Graham Memorial Traveling Fellowship supports training of international surgeons with the potential for future thoracic surgical leadership. The fellowship will run from 2017-2018 and provide a stipend of $75,000 to help cover living and travel expenses for fellows while visiting North American medical centers.
* Candidates must be from other than North America, who have not limited (six months or less) clinical training in North American prior to submitting their application.
* Candidates must have completed their formal training in general and thoracic/cardiovascular surgery but not yet reached a senior position.
Deadline: July 1, 2016
Two AATS Graham Foundation programs are now open for application.
Third John Alexander Research Scholarship provides research, training and experience for North American surgeons committed to pursuing an academic career in cardiothoracic surgery. This two-year scholarship will run from July 1, 2017 - June 30, 2019 and provides an annual $80,000 stipend to the host institution.
* Applications must be submitted during the candidate’s first two years in an academic position.
* Research must occur within the first three years after completion of an approved North American cardiothoracic residency.
Deadline: July 1, 2016
Evarts A. Graham Memorial Traveling Fellowship supports training of international surgeons with the potential for future thoracic surgical leadership. The fellowship will run from 2017-2018 and provide a stipend of $75,000 to help cover living and travel expenses for fellows while visiting North American medical centers.
* Candidates must be from other than North America, who have not limited (six months or less) clinical training in North American prior to submitting their application.
* Candidates must have completed their formal training in general and thoracic/cardiovascular surgery but not yet reached a senior position.
Deadline: July 1, 2016
Housing & Registration Open: Inaugural Patient Safety Course
June 24-25, 2016
Renaissance Boston Waterfront Hotel
Boston, MA
Co-Directors
Thoralf M. Sundt, III, MD
Steven Yule, PhD
Program Committee
David J. Bunnell, PA-C, APACVS
David C. Fitzgerald, CCP, AMSECT
Jake Jaquiss, MD
M. Blair Marshall, MD
Shannon Pengel, RN
Kenneth Shann, CCP, LP, AMSECT
Marco Zenati, MD
Patient Safety is essential for successful surgical care — in cardiothoracic surgery — and all disciplines. In the more than 10 years since the Institute of Medicine made patient safety a priority, little progress has been made in changing culture and practice on the front lines.
This two-day course — including team training and simulation experiences — will make a difference, offering surgical team members practical safety behaviors for improving patient outcomes.
Special Benefits for Team Registration
The Patient Safety program includes team training and simulation experiences. Register three or more members from the same institution and receive one Healthcare Professional registration COMPLIMENTARY. We encourage you to send the entire team to join us in Boston this June.
June 24-25, 2016
Renaissance Boston Waterfront Hotel
Boston, MA
Co-Directors
Thoralf M. Sundt, III, MD
Steven Yule, PhD
Program Committee
David J. Bunnell, PA-C, APACVS
David C. Fitzgerald, CCP, AMSECT
Jake Jaquiss, MD
M. Blair Marshall, MD
Shannon Pengel, RN
Kenneth Shann, CCP, LP, AMSECT
Marco Zenati, MD
Patient Safety is essential for successful surgical care — in cardiothoracic surgery — and all disciplines. In the more than 10 years since the Institute of Medicine made patient safety a priority, little progress has been made in changing culture and practice on the front lines.
This two-day course — including team training and simulation experiences — will make a difference, offering surgical team members practical safety behaviors for improving patient outcomes.
Special Benefits for Team Registration
The Patient Safety program includes team training and simulation experiences. Register three or more members from the same institution and receive one Healthcare Professional registration COMPLIMENTARY. We encourage you to send the entire team to join us in Boston this June.
June 24-25, 2016
Renaissance Boston Waterfront Hotel
Boston, MA
Co-Directors
Thoralf M. Sundt, III, MD
Steven Yule, PhD
Program Committee
David J. Bunnell, PA-C, APACVS
David C. Fitzgerald, CCP, AMSECT
Jake Jaquiss, MD
M. Blair Marshall, MD
Shannon Pengel, RN
Kenneth Shann, CCP, LP, AMSECT
Marco Zenati, MD
Patient Safety is essential for successful surgical care — in cardiothoracic surgery — and all disciplines. In the more than 10 years since the Institute of Medicine made patient safety a priority, little progress has been made in changing culture and practice on the front lines.
This two-day course — including team training and simulation experiences — will make a difference, offering surgical team members practical safety behaviors for improving patient outcomes.
Special Benefits for Team Registration
The Patient Safety program includes team training and simulation experiences. Register three or more members from the same institution and receive one Healthcare Professional registration COMPLIMENTARY. We encourage you to send the entire team to join us in Boston this June.
Clinical Pearl: Increasing Utility of Isopropyl Alcohol for Cutaneous Dyschromia
Practice Gap
Conditions with dyschromia including terra firma-forme dermatosis (TFFD), confluent and reticulate papillomatosis (CARP), and acanthosis nigricans are difficult to distinguish from one another.
Diagnostic Tools
Since its development in 1920, dermatologists have utilized isopropyl alcohol in ways that exceed conventional antimicrobial purposes. If TFFP, CARP, and acanthosis nigricans are suspected, the first step in any algorithmic approach should be to rub the skin with an alcohol pad using firm continuous pressure in an attempt to remove pigmentation. Complete resolution of dyspigmentation strongly supports a diagnosis of TFFD1 and can be curative (Figure). Alcohol can similarly lighten CARP but to a lesser degree than TFFD.2 In contrast, acanthosis nigricans will display minimal to no improvement with isopropyl alcohol.
Practice Implications
Isopropyl alcohol has few side effects and each swab costs less than a dime. It is extremely cost effective compared to biopsy and subsequent pathology and laboratory costs. Patients appreciate a noninvasive initial approach, and it is rewarding to treat a cosmetically disturbing condition with ease.
Swabbing the skin with alcohol pads reflects light and improves visualization of veins that should be avoided during surgery. Alcohol-based gel inhibits bacterial colonization, reduces dermatoscope-related nosocomial infection, and enhances dermoscopic resolution.3 Alcohol swabs quickly remove gentian violet, which aids in porokeratosis diagnosis; the pathognomonic cornoid lamella of porokeratosis retains gentian violet.4 A solution of 70% isopropyl alcohol preserves myiasis larvae better than formalin, which causes larval tissue hardening. Alcohol also can be squeezed into the central punctum in myiasis as a form of treatment.5 In conclusion, alcohol represents a convenient, inexpensive, and helpful tool in the dermatologist’s armamentarium that should not be forgotten.
- Browning J, Rosen T. Terra firma-forme dermatosis revisited. Dermatol Online J. 2005;11:15.
- Berk DR. Confluent and reticulated papillomatosis response to 70% alcohol swabbing. Arch Dermatol. 2011;147:247-248.
- Kelly SC, Purcell SM. Prevention of nosocomial infection during dermoscopy? Dermatol Surg. 2006;32:552-555.
- Thomas CJ, Elston DM. Medical pearl: Gentian violet to highlight the cornoid lamella in disseminated superficial actinic porokeratosis. J Am Acad Dermatol. 2005;52(3, pt 1):513-514.
- Meinking TL, Burkhart CN, Burkhart CG. Changing paradigms in parasitic infections: common dermatological helminthic infections and cutaneous myiasis. Clin Dermatol. 2003;21:407-416.
Practice Gap
Conditions with dyschromia including terra firma-forme dermatosis (TFFD), confluent and reticulate papillomatosis (CARP), and acanthosis nigricans are difficult to distinguish from one another.
Diagnostic Tools
Since its development in 1920, dermatologists have utilized isopropyl alcohol in ways that exceed conventional antimicrobial purposes. If TFFP, CARP, and acanthosis nigricans are suspected, the first step in any algorithmic approach should be to rub the skin with an alcohol pad using firm continuous pressure in an attempt to remove pigmentation. Complete resolution of dyspigmentation strongly supports a diagnosis of TFFD1 and can be curative (Figure). Alcohol can similarly lighten CARP but to a lesser degree than TFFD.2 In contrast, acanthosis nigricans will display minimal to no improvement with isopropyl alcohol.
Practice Implications
Isopropyl alcohol has few side effects and each swab costs less than a dime. It is extremely cost effective compared to biopsy and subsequent pathology and laboratory costs. Patients appreciate a noninvasive initial approach, and it is rewarding to treat a cosmetically disturbing condition with ease.
Swabbing the skin with alcohol pads reflects light and improves visualization of veins that should be avoided during surgery. Alcohol-based gel inhibits bacterial colonization, reduces dermatoscope-related nosocomial infection, and enhances dermoscopic resolution.3 Alcohol swabs quickly remove gentian violet, which aids in porokeratosis diagnosis; the pathognomonic cornoid lamella of porokeratosis retains gentian violet.4 A solution of 70% isopropyl alcohol preserves myiasis larvae better than formalin, which causes larval tissue hardening. Alcohol also can be squeezed into the central punctum in myiasis as a form of treatment.5 In conclusion, alcohol represents a convenient, inexpensive, and helpful tool in the dermatologist’s armamentarium that should not be forgotten.
Practice Gap
Conditions with dyschromia including terra firma-forme dermatosis (TFFD), confluent and reticulate papillomatosis (CARP), and acanthosis nigricans are difficult to distinguish from one another.
Diagnostic Tools
Since its development in 1920, dermatologists have utilized isopropyl alcohol in ways that exceed conventional antimicrobial purposes. If TFFP, CARP, and acanthosis nigricans are suspected, the first step in any algorithmic approach should be to rub the skin with an alcohol pad using firm continuous pressure in an attempt to remove pigmentation. Complete resolution of dyspigmentation strongly supports a diagnosis of TFFD1 and can be curative (Figure). Alcohol can similarly lighten CARP but to a lesser degree than TFFD.2 In contrast, acanthosis nigricans will display minimal to no improvement with isopropyl alcohol.
Practice Implications
Isopropyl alcohol has few side effects and each swab costs less than a dime. It is extremely cost effective compared to biopsy and subsequent pathology and laboratory costs. Patients appreciate a noninvasive initial approach, and it is rewarding to treat a cosmetically disturbing condition with ease.
Swabbing the skin with alcohol pads reflects light and improves visualization of veins that should be avoided during surgery. Alcohol-based gel inhibits bacterial colonization, reduces dermatoscope-related nosocomial infection, and enhances dermoscopic resolution.3 Alcohol swabs quickly remove gentian violet, which aids in porokeratosis diagnosis; the pathognomonic cornoid lamella of porokeratosis retains gentian violet.4 A solution of 70% isopropyl alcohol preserves myiasis larvae better than formalin, which causes larval tissue hardening. Alcohol also can be squeezed into the central punctum in myiasis as a form of treatment.5 In conclusion, alcohol represents a convenient, inexpensive, and helpful tool in the dermatologist’s armamentarium that should not be forgotten.
- Browning J, Rosen T. Terra firma-forme dermatosis revisited. Dermatol Online J. 2005;11:15.
- Berk DR. Confluent and reticulated papillomatosis response to 70% alcohol swabbing. Arch Dermatol. 2011;147:247-248.
- Kelly SC, Purcell SM. Prevention of nosocomial infection during dermoscopy? Dermatol Surg. 2006;32:552-555.
- Thomas CJ, Elston DM. Medical pearl: Gentian violet to highlight the cornoid lamella in disseminated superficial actinic porokeratosis. J Am Acad Dermatol. 2005;52(3, pt 1):513-514.
- Meinking TL, Burkhart CN, Burkhart CG. Changing paradigms in parasitic infections: common dermatological helminthic infections and cutaneous myiasis. Clin Dermatol. 2003;21:407-416.
- Browning J, Rosen T. Terra firma-forme dermatosis revisited. Dermatol Online J. 2005;11:15.
- Berk DR. Confluent and reticulated papillomatosis response to 70% alcohol swabbing. Arch Dermatol. 2011;147:247-248.
- Kelly SC, Purcell SM. Prevention of nosocomial infection during dermoscopy? Dermatol Surg. 2006;32:552-555.
- Thomas CJ, Elston DM. Medical pearl: Gentian violet to highlight the cornoid lamella in disseminated superficial actinic porokeratosis. J Am Acad Dermatol. 2005;52(3, pt 1):513-514.
- Meinking TL, Burkhart CN, Burkhart CG. Changing paradigms in parasitic infections: common dermatological helminthic infections and cutaneous myiasis. Clin Dermatol. 2003;21:407-416.
Higher Risk of Cataracts After Percutaneous Coronary Intervention
NEW YORK (Reuters Health) - The risk of cataracts increases after percutaneous coronary intervention (PCI), suggesting the need for eye protection in patients undergoing these procedures, researchers from Taiwan report.
Although previous studies have identified a link between occupational radiation exposure and excess risk of cataract formation, the research in patients has been more limited. Lead eyeglasses are currently recommended for interventionists, but there are no guidelines for patient eye protection.
Dr. Yu-Tung Huang, from Kaohsiung Medical University,Kaohsiung, Taiwan, and colleagues used data from Taiwan's National Health Insurance research database to evaluate the risk of cataract surgery in 13,807 patients exposed to PCI and 27,614 patients not exposed to PCI.
Patients who underwent PCI were 25% more likely than those not exposed to PCI to have cataract surgery, according to the April 4 JAMA Internal Medicine online report.
The risk of cataract surgery increased with increasing numbers of PCI procedures, from 23% increased risk with one procedure to 29% increased risk with two to four procedures to 43% increased risk with five or more procedures.
"Because this was an observational study," they note, "we cannot establish causation, and there may be unmeasured confounders."
Nevertheless, the researchers conclude, "providing lead eyeglasses to protect patients' eyes, as is already done during cosmetic laser procedures, during the PCI procedures is recommended."
Dr. Huang did not respond to a request for comments.The authors reported no funding or disclosures.
NEW YORK (Reuters Health) - The risk of cataracts increases after percutaneous coronary intervention (PCI), suggesting the need for eye protection in patients undergoing these procedures, researchers from Taiwan report.
Although previous studies have identified a link between occupational radiation exposure and excess risk of cataract formation, the research in patients has been more limited. Lead eyeglasses are currently recommended for interventionists, but there are no guidelines for patient eye protection.
Dr. Yu-Tung Huang, from Kaohsiung Medical University,Kaohsiung, Taiwan, and colleagues used data from Taiwan's National Health Insurance research database to evaluate the risk of cataract surgery in 13,807 patients exposed to PCI and 27,614 patients not exposed to PCI.
Patients who underwent PCI were 25% more likely than those not exposed to PCI to have cataract surgery, according to the April 4 JAMA Internal Medicine online report.
The risk of cataract surgery increased with increasing numbers of PCI procedures, from 23% increased risk with one procedure to 29% increased risk with two to four procedures to 43% increased risk with five or more procedures.
"Because this was an observational study," they note, "we cannot establish causation, and there may be unmeasured confounders."
Nevertheless, the researchers conclude, "providing lead eyeglasses to protect patients' eyes, as is already done during cosmetic laser procedures, during the PCI procedures is recommended."
Dr. Huang did not respond to a request for comments.The authors reported no funding or disclosures.
NEW YORK (Reuters Health) - The risk of cataracts increases after percutaneous coronary intervention (PCI), suggesting the need for eye protection in patients undergoing these procedures, researchers from Taiwan report.
Although previous studies have identified a link between occupational radiation exposure and excess risk of cataract formation, the research in patients has been more limited. Lead eyeglasses are currently recommended for interventionists, but there are no guidelines for patient eye protection.
Dr. Yu-Tung Huang, from Kaohsiung Medical University,Kaohsiung, Taiwan, and colleagues used data from Taiwan's National Health Insurance research database to evaluate the risk of cataract surgery in 13,807 patients exposed to PCI and 27,614 patients not exposed to PCI.
Patients who underwent PCI were 25% more likely than those not exposed to PCI to have cataract surgery, according to the April 4 JAMA Internal Medicine online report.
The risk of cataract surgery increased with increasing numbers of PCI procedures, from 23% increased risk with one procedure to 29% increased risk with two to four procedures to 43% increased risk with five or more procedures.
"Because this was an observational study," they note, "we cannot establish causation, and there may be unmeasured confounders."
Nevertheless, the researchers conclude, "providing lead eyeglasses to protect patients' eyes, as is already done during cosmetic laser procedures, during the PCI procedures is recommended."
Dr. Huang did not respond to a request for comments.The authors reported no funding or disclosures.
Antimalarial resistance can’t be passed on, team says
in mosquito gut
Image by Antoine Nicot
and Jacques Denoyelle
Parasites that develop resistance to the antimalarial drug atovaquone cannot pass this resistance on to their offspring, a new study suggests.
Researchers found that malaria parasites develop resistance to atovaquone via mutations in the mitochondrial cytochrome b complex.
However, these mutations also prevent female parasites from reproducing, so the resistance cannot be passed on to future generations.
Geoff McFadden, PhD, of the University of Melbourne in Victoria, Australia, and his colleagues reported these findings in Science.
“These results are very exciting because the spread of drug resistance is currently destroying our ability to control malaria,” Dr McFadden said.
“We now understand the particular genetic mutation that gave rise to drug resistance in some malaria parasite populations and how it eventually kills them in the mosquito, providing new targets for the development of drugs. So the development of drug resistance may not be a major problem if the resistance cannot spread, meaning the drug atovaquone could be more widely used in malaria control.”
To conduct this study, Dr McFadden and his colleagues analyzed 3 atovaquone-resistant strains of Plasmodium berghei, a malaria parasite that infects rodents. Each strain contained a different mutation in cytochrome b.
The researchers found that 2 of the mutations resulted in developmental defects in the parasite zygotes, and the third mutation resulted in complete infertility in the parasites due to severely impaired female germ cells.
Cross breeding parasites with and without these mutations showed that the mutations are not passed on to offspring. From 44 separate transmission attempts involving 750 mosquito bites, transmission of atovaquone resistance was only observed once, and this mutant was unable to transmit further, despite 7 attempts.
The researchers said it appears that atovaquone-resistant mutations severely impair the lifecycle of the parasites when they are living in mosquito hosts, so these mutations cannot be passed on.
In the human malaria parasite Plasmodium falciparum, the researchers identified similar mutations that impaired the ability of the parasites to infect mosquitos, as well as the number of oocysts produced when infection did occur. 
in mosquito gut
Image by Antoine Nicot
and Jacques Denoyelle
Parasites that develop resistance to the antimalarial drug atovaquone cannot pass this resistance on to their offspring, a new study suggests.
Researchers found that malaria parasites develop resistance to atovaquone via mutations in the mitochondrial cytochrome b complex.
However, these mutations also prevent female parasites from reproducing, so the resistance cannot be passed on to future generations.
Geoff McFadden, PhD, of the University of Melbourne in Victoria, Australia, and his colleagues reported these findings in Science.
“These results are very exciting because the spread of drug resistance is currently destroying our ability to control malaria,” Dr McFadden said.
“We now understand the particular genetic mutation that gave rise to drug resistance in some malaria parasite populations and how it eventually kills them in the mosquito, providing new targets for the development of drugs. So the development of drug resistance may not be a major problem if the resistance cannot spread, meaning the drug atovaquone could be more widely used in malaria control.”
To conduct this study, Dr McFadden and his colleagues analyzed 3 atovaquone-resistant strains of Plasmodium berghei, a malaria parasite that infects rodents. Each strain contained a different mutation in cytochrome b.
The researchers found that 2 of the mutations resulted in developmental defects in the parasite zygotes, and the third mutation resulted in complete infertility in the parasites due to severely impaired female germ cells.
Cross breeding parasites with and without these mutations showed that the mutations are not passed on to offspring. From 44 separate transmission attempts involving 750 mosquito bites, transmission of atovaquone resistance was only observed once, and this mutant was unable to transmit further, despite 7 attempts.
The researchers said it appears that atovaquone-resistant mutations severely impair the lifecycle of the parasites when they are living in mosquito hosts, so these mutations cannot be passed on.
In the human malaria parasite Plasmodium falciparum, the researchers identified similar mutations that impaired the ability of the parasites to infect mosquitos, as well as the number of oocysts produced when infection did occur.
in mosquito gut
Image by Antoine Nicot
and Jacques Denoyelle
Parasites that develop resistance to the antimalarial drug atovaquone cannot pass this resistance on to their offspring, a new study suggests.
Researchers found that malaria parasites develop resistance to atovaquone via mutations in the mitochondrial cytochrome b complex.
However, these mutations also prevent female parasites from reproducing, so the resistance cannot be passed on to future generations.
Geoff McFadden, PhD, of the University of Melbourne in Victoria, Australia, and his colleagues reported these findings in Science.
“These results are very exciting because the spread of drug resistance is currently destroying our ability to control malaria,” Dr McFadden said.
“We now understand the particular genetic mutation that gave rise to drug resistance in some malaria parasite populations and how it eventually kills them in the mosquito, providing new targets for the development of drugs. So the development of drug resistance may not be a major problem if the resistance cannot spread, meaning the drug atovaquone could be more widely used in malaria control.”
To conduct this study, Dr McFadden and his colleagues analyzed 3 atovaquone-resistant strains of Plasmodium berghei, a malaria parasite that infects rodents. Each strain contained a different mutation in cytochrome b.
The researchers found that 2 of the mutations resulted in developmental defects in the parasite zygotes, and the third mutation resulted in complete infertility in the parasites due to severely impaired female germ cells.
Cross breeding parasites with and without these mutations showed that the mutations are not passed on to offspring. From 44 separate transmission attempts involving 750 mosquito bites, transmission of atovaquone resistance was only observed once, and this mutant was unable to transmit further, despite 7 attempts.
The researchers said it appears that atovaquone-resistant mutations severely impair the lifecycle of the parasites when they are living in mosquito hosts, so these mutations cannot be passed on.
In the human malaria parasite Plasmodium falciparum, the researchers identified similar mutations that impaired the ability of the parasites to infect mosquitos, as well as the number of oocysts produced when infection did occur.
Gut bacteria could help prevent lymphoma, other cancers
New research published in PLOS ONE suggests certain intestinal bacteria could potentially be used to reduce the risk of lymphomas and other cancers.
Researchers believe doctors might be able to reduce a person’s risk of these cancers by analyzing the levels and types of intestinal bacteria in the body and then prescribing probiotics to replace or bolster the amount of bacteria with anti-inflammatory properties.
“It is not invasive and rather easy to do,” said study author Robert Schiestl, PhD, of the University of California, Los Angeles.
Dr Schiestl and his colleagues isolated a bacterium called Lactobacillus johnsonii 456, which is the most abundant of the beneficial bacteria.
The team found this bacterium reduced gene damage and inflammation, which, as they pointed out, plays a key role in cancers and other diseases.
Previous research led by Dr Schiestl presented the first evidence of a relationship between intestinal microbiota and the onset of lymphoma.
The new study explains how this microbiota might delay the onset of cancer and suggests that probiotic supplements could help keep cancer from forming.
For both studies, Dr Schiestl and his team used mice that had mutations in the gene ATM, which made them susceptible to a neurologic disorder called ataxia telangiectasia. The disorder is associated with a high incidence of leukemias, lymphomas, and other cancers.
The mice were divided into two groups—one that was given only anti-inflammatory bacteria and another that received a mix of inflammatory and anti-inflammatory microbes that typically co-exist in the intestines.
With their previous study, Dr Schiestl and his team showed that, in the mice with more of the beneficial bacteria, the lymphoma took significantly longer to form.
For the new study, the researchers analyzed metabolites in the mice’s urine and feces and found the mice that were receiving only the beneficial microbiota produced metabolites that are known to prevent cancer.
Those mice also had more efficient fat and oxidative metabolism, which the researchers believe might also lower the risk for cancer.
Among the other results, in the mice receiving only the good bacteria, lymphoma formed only half as quickly as it did in the other mice. In addition, mice with the good bacteria lived 4 times longer and had less DNA damage and inflammation.
The researchers said these findings lend credence to the idea that manipulating microbial composition could be used to prevent or alleviate cancer susceptibility. They hope that, in the future, probiotic supplements could be chemopreventive for the average person and decrease tumor incidence in cancer-susceptible populations.
The University of California, Los Angeles has a patent pending on the use of Lactobacillus johnsonii 456 as an anti-inflammatory agent.
New research published in PLOS ONE suggests certain intestinal bacteria could potentially be used to reduce the risk of lymphomas and other cancers.
Researchers believe doctors might be able to reduce a person’s risk of these cancers by analyzing the levels and types of intestinal bacteria in the body and then prescribing probiotics to replace or bolster the amount of bacteria with anti-inflammatory properties.
“It is not invasive and rather easy to do,” said study author Robert Schiestl, PhD, of the University of California, Los Angeles.
Dr Schiestl and his colleagues isolated a bacterium called Lactobacillus johnsonii 456, which is the most abundant of the beneficial bacteria.
The team found this bacterium reduced gene damage and inflammation, which, as they pointed out, plays a key role in cancers and other diseases.
Previous research led by Dr Schiestl presented the first evidence of a relationship between intestinal microbiota and the onset of lymphoma.
The new study explains how this microbiota might delay the onset of cancer and suggests that probiotic supplements could help keep cancer from forming.
For both studies, Dr Schiestl and his team used mice that had mutations in the gene ATM, which made them susceptible to a neurologic disorder called ataxia telangiectasia. The disorder is associated with a high incidence of leukemias, lymphomas, and other cancers.
The mice were divided into two groups—one that was given only anti-inflammatory bacteria and another that received a mix of inflammatory and anti-inflammatory microbes that typically co-exist in the intestines.
With their previous study, Dr Schiestl and his team showed that, in the mice with more of the beneficial bacteria, the lymphoma took significantly longer to form.
For the new study, the researchers analyzed metabolites in the mice’s urine and feces and found the mice that were receiving only the beneficial microbiota produced metabolites that are known to prevent cancer.
Those mice also had more efficient fat and oxidative metabolism, which the researchers believe might also lower the risk for cancer.
Among the other results, in the mice receiving only the good bacteria, lymphoma formed only half as quickly as it did in the other mice. In addition, mice with the good bacteria lived 4 times longer and had less DNA damage and inflammation.
The researchers said these findings lend credence to the idea that manipulating microbial composition could be used to prevent or alleviate cancer susceptibility. They hope that, in the future, probiotic supplements could be chemopreventive for the average person and decrease tumor incidence in cancer-susceptible populations.
The University of California, Los Angeles has a patent pending on the use of Lactobacillus johnsonii 456 as an anti-inflammatory agent.
New research published in PLOS ONE suggests certain intestinal bacteria could potentially be used to reduce the risk of lymphomas and other cancers.
Researchers believe doctors might be able to reduce a person’s risk of these cancers by analyzing the levels and types of intestinal bacteria in the body and then prescribing probiotics to replace or bolster the amount of bacteria with anti-inflammatory properties.
“It is not invasive and rather easy to do,” said study author Robert Schiestl, PhD, of the University of California, Los Angeles.
Dr Schiestl and his colleagues isolated a bacterium called Lactobacillus johnsonii 456, which is the most abundant of the beneficial bacteria.
The team found this bacterium reduced gene damage and inflammation, which, as they pointed out, plays a key role in cancers and other diseases.
Previous research led by Dr Schiestl presented the first evidence of a relationship between intestinal microbiota and the onset of lymphoma.
The new study explains how this microbiota might delay the onset of cancer and suggests that probiotic supplements could help keep cancer from forming.
For both studies, Dr Schiestl and his team used mice that had mutations in the gene ATM, which made them susceptible to a neurologic disorder called ataxia telangiectasia. The disorder is associated with a high incidence of leukemias, lymphomas, and other cancers.
The mice were divided into two groups—one that was given only anti-inflammatory bacteria and another that received a mix of inflammatory and anti-inflammatory microbes that typically co-exist in the intestines.
With their previous study, Dr Schiestl and his team showed that, in the mice with more of the beneficial bacteria, the lymphoma took significantly longer to form.
For the new study, the researchers analyzed metabolites in the mice’s urine and feces and found the mice that were receiving only the beneficial microbiota produced metabolites that are known to prevent cancer.
Those mice also had more efficient fat and oxidative metabolism, which the researchers believe might also lower the risk for cancer.
Among the other results, in the mice receiving only the good bacteria, lymphoma formed only half as quickly as it did in the other mice. In addition, mice with the good bacteria lived 4 times longer and had less DNA damage and inflammation.
The researchers said these findings lend credence to the idea that manipulating microbial composition could be used to prevent or alleviate cancer susceptibility. They hope that, in the future, probiotic supplements could be chemopreventive for the average person and decrease tumor incidence in cancer-susceptible populations.
The University of California, Los Angeles has a patent pending on the use of Lactobacillus johnsonii 456 as an anti-inflammatory agent.
PD-1 inhibitor granted priority review for cHL
Photo courtesy of Business Wire
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application seeking to expand use of the PD-1 inhibitor nivolumab (Opdivo) to patients with previously treated classical Hodgkin lymphoma (cHL).
A priority review designation means the FDA’s goal is to take action on an application within 6 months, rather than the 10 months typically taken for a standard review.
To grant an application priority review, the FDA must believe the drug would provide a significant improvement in the treatment, diagnosis, or prevention of a serious condition.
About nivolumab
Nivolumab is an inhibitor that binds to the checkpoint receptor PD-1, which is expressed on activated T cells. The drug prevents PD-L1 and PD-L2 from binding, thereby preventing the PD-1 pathway’s suppressive signaling on the immune system, including interference with an anti-tumor immune response.
Nivolumab is being developed by Bristol-Myers Squibb. The drug currently has regulatory approval in 48 countries.
In the US, nivolumab is approved—both as a single agent and in combination—to treat certain patients with melanoma, non-small-cell lung cancer, or advanced renal cell carcinoma.
According to Bristol-Myers Squibb, nivolumab has the potential to become first PD-1 inhibitor approved for a hematologic malignancy in the US.
The supplemental biologics license application for nivolumab included data from the phase 2 trial CheckMate 205. In this ongoing trial, researchers are evaluating nivolumab in patients with relapsed or refractory cHL who have received an autologous stem cell transplant and brentuximab vedotin.
Data from this trial are expected to be presented at a medical meeting later this year.
The FDA previously granted nivolumab breakthrough therapy designation for cHL. The FDA’s breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.
Photo courtesy of Business Wire
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application seeking to expand use of the PD-1 inhibitor nivolumab (Opdivo) to patients with previously treated classical Hodgkin lymphoma (cHL).
A priority review designation means the FDA’s goal is to take action on an application within 6 months, rather than the 10 months typically taken for a standard review.
To grant an application priority review, the FDA must believe the drug would provide a significant improvement in the treatment, diagnosis, or prevention of a serious condition.
About nivolumab
Nivolumab is an inhibitor that binds to the checkpoint receptor PD-1, which is expressed on activated T cells. The drug prevents PD-L1 and PD-L2 from binding, thereby preventing the PD-1 pathway’s suppressive signaling on the immune system, including interference with an anti-tumor immune response.
Nivolumab is being developed by Bristol-Myers Squibb. The drug currently has regulatory approval in 48 countries.
In the US, nivolumab is approved—both as a single agent and in combination—to treat certain patients with melanoma, non-small-cell lung cancer, or advanced renal cell carcinoma.
According to Bristol-Myers Squibb, nivolumab has the potential to become first PD-1 inhibitor approved for a hematologic malignancy in the US.
The supplemental biologics license application for nivolumab included data from the phase 2 trial CheckMate 205. In this ongoing trial, researchers are evaluating nivolumab in patients with relapsed or refractory cHL who have received an autologous stem cell transplant and brentuximab vedotin.
Data from this trial are expected to be presented at a medical meeting later this year.
The FDA previously granted nivolumab breakthrough therapy designation for cHL. The FDA’s breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.
Photo courtesy of Business Wire
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application seeking to expand use of the PD-1 inhibitor nivolumab (Opdivo) to patients with previously treated classical Hodgkin lymphoma (cHL).
A priority review designation means the FDA’s goal is to take action on an application within 6 months, rather than the 10 months typically taken for a standard review.
To grant an application priority review, the FDA must believe the drug would provide a significant improvement in the treatment, diagnosis, or prevention of a serious condition.
About nivolumab
Nivolumab is an inhibitor that binds to the checkpoint receptor PD-1, which is expressed on activated T cells. The drug prevents PD-L1 and PD-L2 from binding, thereby preventing the PD-1 pathway’s suppressive signaling on the immune system, including interference with an anti-tumor immune response.
Nivolumab is being developed by Bristol-Myers Squibb. The drug currently has regulatory approval in 48 countries.
In the US, nivolumab is approved—both as a single agent and in combination—to treat certain patients with melanoma, non-small-cell lung cancer, or advanced renal cell carcinoma.
According to Bristol-Myers Squibb, nivolumab has the potential to become first PD-1 inhibitor approved for a hematologic malignancy in the US.
The supplemental biologics license application for nivolumab included data from the phase 2 trial CheckMate 205. In this ongoing trial, researchers are evaluating nivolumab in patients with relapsed or refractory cHL who have received an autologous stem cell transplant and brentuximab vedotin.
Data from this trial are expected to be presented at a medical meeting later this year.
The FDA previously granted nivolumab breakthrough therapy designation for cHL. The FDA’s breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.
Study provides new insight into malaria transmission
infecting a red blood cell
Image courtesy of St. Jude
Children’s Research Hospital
Research published in PNAS helps explain how the malaria parasite Plasmodium falciparum undergoes the changes that enable transmission of the parasite from humans to mosquitoes.
Investigators determined how the parasite transforms its own structure and the structure of a host red blood cell so the parasite can hide from the body’s normal defenses and later re-enter the bloodstream for transmission via mosquito bite.
The team believes that, by understanding this process, it may be possible to inhibit the blood cell’s transformation.
“Once you understand the molecular mechanisms, it becomes easier to find drugs to target them,” said Sulin Zhang, PhD, of Pennsylvania State University in University Park.
Dr Zhang developed the computational methods used to understand the physical transformations in the infected red blood cells that allow them to avoid removal in the spleen and prepare for transmission to a mosquito host.
He and his colleagues knew that healthy red blood cells are able to squeeze through small slits in the spleen, but damaged and aging red blood cells cannot and are filtered out and removed from the circulation.
To avoid this fate, the sexual stage malaria parasite first makes the red blood cell rigid and hides out in deep tissue. Then, when the parasite is mature, the infected red blood cells become flexible and elastic, ready to be picked up by a mosquito for disease transmission.
To understand these changes, the investigators prepared samples of parasites at each stage and studied the changing microstructure using atomic force microscopy.
This revealed changes in the organization of a meshwork of tiny spring-like proteins in the blood cell membrane. When the parasite is ready for transmission, it reverses the structural changes.
The team then turned to Dr Zhang, who developed a model to explain how subtle changes to the molecular structure of the spring-like proteins were sufficient to make the red blood cell either rigid or flexible.
The investigators are continuing to use Dr Zhang’s model to simulate the overall shapes and the flow dynamics of infected red blood cells in the bloodstream, providing information that could aid researchers looking to inhibit the malaria parasite’s spread.
infecting a red blood cell
Image courtesy of St. Jude
Children’s Research Hospital
Research published in PNAS helps explain how the malaria parasite Plasmodium falciparum undergoes the changes that enable transmission of the parasite from humans to mosquitoes.
Investigators determined how the parasite transforms its own structure and the structure of a host red blood cell so the parasite can hide from the body’s normal defenses and later re-enter the bloodstream for transmission via mosquito bite.
The team believes that, by understanding this process, it may be possible to inhibit the blood cell’s transformation.
“Once you understand the molecular mechanisms, it becomes easier to find drugs to target them,” said Sulin Zhang, PhD, of Pennsylvania State University in University Park.
Dr Zhang developed the computational methods used to understand the physical transformations in the infected red blood cells that allow them to avoid removal in the spleen and prepare for transmission to a mosquito host.
He and his colleagues knew that healthy red blood cells are able to squeeze through small slits in the spleen, but damaged and aging red blood cells cannot and are filtered out and removed from the circulation.
To avoid this fate, the sexual stage malaria parasite first makes the red blood cell rigid and hides out in deep tissue. Then, when the parasite is mature, the infected red blood cells become flexible and elastic, ready to be picked up by a mosquito for disease transmission.
To understand these changes, the investigators prepared samples of parasites at each stage and studied the changing microstructure using atomic force microscopy.
This revealed changes in the organization of a meshwork of tiny spring-like proteins in the blood cell membrane. When the parasite is ready for transmission, it reverses the structural changes.
The team then turned to Dr Zhang, who developed a model to explain how subtle changes to the molecular structure of the spring-like proteins were sufficient to make the red blood cell either rigid or flexible.
The investigators are continuing to use Dr Zhang’s model to simulate the overall shapes and the flow dynamics of infected red blood cells in the bloodstream, providing information that could aid researchers looking to inhibit the malaria parasite’s spread.
infecting a red blood cell
Image courtesy of St. Jude
Children’s Research Hospital
Research published in PNAS helps explain how the malaria parasite Plasmodium falciparum undergoes the changes that enable transmission of the parasite from humans to mosquitoes.
Investigators determined how the parasite transforms its own structure and the structure of a host red blood cell so the parasite can hide from the body’s normal defenses and later re-enter the bloodstream for transmission via mosquito bite.
The team believes that, by understanding this process, it may be possible to inhibit the blood cell’s transformation.
“Once you understand the molecular mechanisms, it becomes easier to find drugs to target them,” said Sulin Zhang, PhD, of Pennsylvania State University in University Park.
Dr Zhang developed the computational methods used to understand the physical transformations in the infected red blood cells that allow them to avoid removal in the spleen and prepare for transmission to a mosquito host.
He and his colleagues knew that healthy red blood cells are able to squeeze through small slits in the spleen, but damaged and aging red blood cells cannot and are filtered out and removed from the circulation.
To avoid this fate, the sexual stage malaria parasite first makes the red blood cell rigid and hides out in deep tissue. Then, when the parasite is mature, the infected red blood cells become flexible and elastic, ready to be picked up by a mosquito for disease transmission.
To understand these changes, the investigators prepared samples of parasites at each stage and studied the changing microstructure using atomic force microscopy.
This revealed changes in the organization of a meshwork of tiny spring-like proteins in the blood cell membrane. When the parasite is ready for transmission, it reverses the structural changes.
The team then turned to Dr Zhang, who developed a model to explain how subtle changes to the molecular structure of the spring-like proteins were sufficient to make the red blood cell either rigid or flexible.
The investigators are continuing to use Dr Zhang’s model to simulate the overall shapes and the flow dynamics of infected red blood cells in the bloodstream, providing information that could aid researchers looking to inhibit the malaria parasite’s spread.
Resident‐Created Hospitalist Curriculum
Hospital medicine has grown tremendously since its inception in the 1990s.[1, 2] This expansion has led to the firm establishment of hospitalists in medical education, quality improvement (QI), research, subspecialty comanagement, and administration.[3, 4, 5]
This growth has also created new challenges. The training needs for the next generation of hospitalists are changing given the expanded clinical duties expected of hospitalists.[6, 7, 8] Prior surveys have suggested that some graduates employed as hospitalists have reported feeling underprepared in the areas of surgical comanagement, neurology, geriatrics, palliative care, and navigating the interdisciplinary care system.[9, 10]
In keeping with national trends, the number of residents interested in hospital medicine at our institution has dramatically increased. As internal medicine residents interested in careers in hospitalist medicine, we felt that improving hospitalist training at our institution was imperative given the increasing scope of practice and job competitiveness.[11, 12] We therefore sought to design and implement a hospitalist curriculum within our residency. In this article, we describe the genesis of our program, our final product, and the challenges of creating a curriculum while being internal medicine residents.
METHODS
Needs Assessment
To improve hospitalist training at our institution, we first performed a needs assessment. We contacted recent hospitalist graduates and current faculty to identify aspects of their clinical duties that may have been underemphasized during their training. Next, we performed a literature search in PubMed using the combined terms of hospitalist, hospital medicine, residency, education, training gaps, or curriculum. Based on these efforts, we developed a resident survey that assessed their attitudes toward various components of a potential curriculum. The survey was sent to all categorical internal medicine residents at our institution in December 2014. The survey specified that the respondents only include those who were interested in careers in hospital medicine. Responses were measured using a 5‐point Likert scale (1 = least important to 5 = most important).
Curriculum Development
Our intention was to develop a well‐rounded program that utilized mentorship, research, and clinical experience to augment our learner's knowledge and skills for a successful, long‐term career in the increasingly competitive field of hospital medicine. When designing our curriculum, we accounted for our program's current rotational requirements and local culture. Several previously identified underemphasized areas within hospital medicine, such as palliative care and neurology, were already required rotations at our program.[3, 4, 5] Therefore, any proposed curricular changes would need to mold into program requirements while still providing a preparatory experience in hospital medicine beyond what our current rotations offered. We felt this could be accomplished by including rotations that could provide specific skills pertinent to hospital medicine, such as ultrasound diagnostics or QI.
| Rotation | Non‐SHAPE | SHAPE |
|---|---|---|
| ||
| ICU | At least 12 weeks | At least 16 weeks |
| Medical wards | At least 16 weeks | At least 16 weeks |
| Ultrasound diagnostics | Elective | Required |
| Quality improvement | Elective | Required |
| Surgical comanagement | Elective | Required |
| Medicine consult | Elective | Required |
| Neurology | Required | Required |
| Palliative care | Required | Required |
Meeting With Stakeholders
We presented our curriculum proposal to the chief of the Stanford Hospital Medicine Program. We identified her early in the process to be our primary mentor, and she proved instrumental in being an advocate. After several meetings with the hospitalist group to further develop our program, we presented it to the residency program leadership who helped us to finalize our program.
RESULTS
Needs Assessment
Twenty‐two out of 111 categorical residents in our program (19.8%) identified themselves as interested in hospital medicine and responded to the survey. There were several areas of a potential hospitalist curriculum that the residents identified as important (defined as 4 or 5 on a 5‐point Likert scale). These areas included mentorship (90.9% of residents; mean 4.6, standard deviation [SD] 0.7), opportunities to teach (86.3%; mean 4.4, SD 0.9), and the establishment of a formal hospitalist curriculum (85.7%; mean 4.2, SD 0.8). The residents also identified several rotations that would be beneficial (defined as a 4 or 5 on a 5‐point Likert scale). These included medicine consult/procedures team (95.5% of residents; mean 4.7, SD 0.6), point‐of‐care ultrasound diagnostics (90.8%; mean 4.7, SD 0.8), and a community hospitalist preceptorship (86.4%; mean 4.4, SD 1.0). The residents also identified several rotations deemed to be of lesser benefit. These rotations included inpatient neurology (only 27.3% of residents; mean 3.2, SD 0.8) and palliative care (50.0%; mean 3.5, SD 1.0).
The Final Product: A Hospitalist Training Curriculum
Based on the needs assessment and meetings with program leadership, we designed a hospitalist program and named it the Stanford Hospitalist Advanced Practice and Education (SHAPE) program. The program was based on 3 core principles: (1) clinical excellence: by training in hospitalist‐relevant clinical areas, (2) academic development: with required research, QI, and teaching, and (3) career mentorship.
Clinical Excellence By Training in Hospitalist‐Relevant Clinical Areas
The SHAPE curriculum builds off of our institution's current curriculum with additional required rotations to improve the resident's skillsets. These included ultrasound diagnostics, surgical comanagement, and QI (Box 1). Given that some hospitalists work in an open intensive care unit (ICU), we increased the amount of required ICU time to provide expanded procedural and critical care experiences. The residents also receive 10 seminars focused on hospital medicine, including patient safety, QI, and career development (Box 1).
Box
The Stanford Hospitalist Advanced Practice and Education (SHAPE) program curriculum. Members of the program are required to complete the requirements listed before the end of their third year. Note that the clinical rotations are spread over the 3 years of residency.
Stanford Hospitalist Advanced Practice and Education Required Clinical Rotations
- Medicine Consult (24 weeks)
- Critical Care (16 weeks)
- Ultrasound Diagnostics (2 weeks)
- Quality Improvement (4 weeks)
- Inpatient Neurology (2 weeks)
- Palliative Care (2 weeks)
- Surgical Comanagement (2 weeks)
Required Nonclinical Work
- Quality improvement, clinical or educational project with a presentation at an academic conference or manuscript submission in a peer‐reviewed journal
- Enrollment in the Stanford Faculty Development Center workshop on effective clinical teaching
- Attendance at the hospitalist lecture series (10 lectures): patient safety, hospital efficiency, fundamentals of perioperative medicine, healthcare structure and changing reimbursement patterns, patient handoff, career development, prevention of burnout, inpatient nutrition, hospitalist research, and lean modeling in the hospital setting
Mentorship
- Each participant is matched with 3 hospitalist mentors in order to provide comprehensive career and personal mentorship
Academic Development With Required Research and Teaching
SHAPE program residents are required to develop a QI, education, or clinical research project before graduation. They are required to present their work at a hospitalist conference or submit to a peer‐reviewed journal. They are also encouraged to attend the Society of Hospital Medicine annual meeting for their own career development.
SHAPE program residents also have increased opportunities to improve their teaching skills. The residents are enrolled in a clinical teaching workshop. Furthermore, the residents are responsible for leading regular lectures regarding common inpatient conditions for first‐ and second‐year medical students enrolled in a transitions‐of‐care elective.
Career Mentorship
Each resident is paired with 3 faculty hospitalists who have different areas of expertise (ie, clinical teaching, surgical comanagement, QI). They individually meet on a quarterly basis to discuss their career development and research projects. The SHAPE program will also host an annual resume‐development and career workshop.
SHAPE Resident Characteristics
In its first year, 13 of 25 residents (52%) interested in hospital medicine enrolled in the program. The SHAPE residents were predominantly second‐year residents (11 residents, 84.6%).
Among the 12 residents who did not enroll, there were 7 seniors (58.3%) who would soon be graduating and would not be eligible.
DISCUSSION
The training needs of aspiring hospitalists are changing as the scope of hospital medicine has expanded.[6] Residency programs can facilitate this by implementing a hospitalist curriculum that augments training and provides focused mentorship.[13, 14] An emphasis on resident leadership within these programs ensures positive housestaff buy‐in and satisfaction.
There were several key lessons we learned while designing our curriculum because of our unique role as residents and curriculum founders. This included the early engagement of departmental leadership as mentors. They assisted us in integrating our program within the existing internal medicine residency and the selection of electives. It was also imperative to secure adequate buy‐in from the academic hospitalists at our institution, as they would be our primary source of faculty mentors and lecturers.
A second challenge was balancing curriculum requirements and ensuring adequate buy‐in from our residents. The residents had fewer electives over their second and third years. However, this was balanced by the fact that the residents were given first preference on historically desirable rotations at our institution (including ultrasound, medicine consult, and QI). Furthermore, we purposefully included current resident opinions when performing our needs assessment to ensure adequate buy‐in. Surprisingly, the residents found several key rotations to be of low importance in our needs assessment, such as palliative care and inpatient neurology. Although this may seem confounding, several of these rotations (ie, neurology and palliative care) are already required of all residents at our program. It may be that some residents feel comfortable in these areas based on their previous experiences. Alternatively, this result may represent a lack of knowledge on the residents' part of what skill sets are imperative for career hospitalists. [4, 6]
Finally, we recognize that our program was based on our local needs assessment. Other residency programs may already have similar curricula built into their rotation schedule. In those instances, a hospitalist curriculum that emphasizes scholarly advancement and mentorship may be more appropriate.
CONCLUSIONS AND FUTURE DIRECTIONS
At out institution, we have created a hospitalist program designed to train the next generation of hospitalists with improved clinical, research, and teaching skills. Our cohort of residents will be observed over the next year, and we will administer a follow‐up study to assess the effectiveness of the program.
Acknowledgements
The authors acknowledge Karina Delgado, program manager at Stanford's internal medicine residency, for providing data on recent graduate plans.
Disclosures: Andre Kumar, MD, and Andrea Smeraglio, MD, are cofirst authors. The authors report no conflicts of interest.
- . The hospitalist field turns 15: new opportunities and challenges. J Hosp Med. 2011;6(4):10–13.
- , , , , . The spectrum of community based hospitalist practice: A call to tailor internal medicine residency training. Arch Intern Med. 2007;167:727–729.
- , , , . Health care market trends and the evolution of hospitalist use and roles. J Gen Intern Med. 2005;20(2):101–107.
- , , , . Survey of the National Association of Inpatient Physicians. Ann Intern Med. 1999:343–349.
- , . Hospitalist educators: future of inpatient internal medicine training. Mt Sinai J Med. 2008;75(5):430–435.
- , , , , . Fulfilling the promise of hospital medicine: tailoring internal medicine training to address hospitalists' needs. J Gen Intern Med. 2008;23(7):1110–1115.
- , , , , . Closing the gap between internal medicine training and practice: recommendations from recent graduates. Am J Med. 2005;118(6):680–685
- , , , et al. Curricular content of internal medicine residency programs: a nationwide report. Am J Med. 2014;127(12):1247–1254.
- , , , . Hospitalists' perceptions of their residency training needs: results of a national survey. Am J Med. 2001;111(3):247–254.
- , , , et al. Reforming internal medicine residency training: a report from the Society of General Internal Medicine's Task Force for Residency Reform. J Gen Intern Med. 2005;20(12):1165–1172.
- , . Clinical hospital medicine fellowships: perspectives of employers, hospitalists, and medicine residents. J Hosp Med. 2008;3(1):28–34.
- , , , , , . Challenges and opportunities in academic hospital medicine: report from the Academic hospital medicine Summit. J Hosp Med. 2009;4(4):240–246.
- , , . Achieving hospital medicine's promise through internal medicine residency redesign. Mt Sinai J Med. 2008;75(5):436–441.
- , , , , . Training Future Hospitalists. Cult Med. 1999;171(12):367–370.
Hospital medicine has grown tremendously since its inception in the 1990s.[1, 2] This expansion has led to the firm establishment of hospitalists in medical education, quality improvement (QI), research, subspecialty comanagement, and administration.[3, 4, 5]
This growth has also created new challenges. The training needs for the next generation of hospitalists are changing given the expanded clinical duties expected of hospitalists.[6, 7, 8] Prior surveys have suggested that some graduates employed as hospitalists have reported feeling underprepared in the areas of surgical comanagement, neurology, geriatrics, palliative care, and navigating the interdisciplinary care system.[9, 10]
In keeping with national trends, the number of residents interested in hospital medicine at our institution has dramatically increased. As internal medicine residents interested in careers in hospitalist medicine, we felt that improving hospitalist training at our institution was imperative given the increasing scope of practice and job competitiveness.[11, 12] We therefore sought to design and implement a hospitalist curriculum within our residency. In this article, we describe the genesis of our program, our final product, and the challenges of creating a curriculum while being internal medicine residents.
METHODS
Needs Assessment
To improve hospitalist training at our institution, we first performed a needs assessment. We contacted recent hospitalist graduates and current faculty to identify aspects of their clinical duties that may have been underemphasized during their training. Next, we performed a literature search in PubMed using the combined terms of hospitalist, hospital medicine, residency, education, training gaps, or curriculum. Based on these efforts, we developed a resident survey that assessed their attitudes toward various components of a potential curriculum. The survey was sent to all categorical internal medicine residents at our institution in December 2014. The survey specified that the respondents only include those who were interested in careers in hospital medicine. Responses were measured using a 5‐point Likert scale (1 = least important to 5 = most important).
Curriculum Development
Our intention was to develop a well‐rounded program that utilized mentorship, research, and clinical experience to augment our learner's knowledge and skills for a successful, long‐term career in the increasingly competitive field of hospital medicine. When designing our curriculum, we accounted for our program's current rotational requirements and local culture. Several previously identified underemphasized areas within hospital medicine, such as palliative care and neurology, were already required rotations at our program.[3, 4, 5] Therefore, any proposed curricular changes would need to mold into program requirements while still providing a preparatory experience in hospital medicine beyond what our current rotations offered. We felt this could be accomplished by including rotations that could provide specific skills pertinent to hospital medicine, such as ultrasound diagnostics or QI.
| Rotation | Non‐SHAPE | SHAPE |
|---|---|---|
| ||
| ICU | At least 12 weeks | At least 16 weeks |
| Medical wards | At least 16 weeks | At least 16 weeks |
| Ultrasound diagnostics | Elective | Required |
| Quality improvement | Elective | Required |
| Surgical comanagement | Elective | Required |
| Medicine consult | Elective | Required |
| Neurology | Required | Required |
| Palliative care | Required | Required |
Meeting With Stakeholders
We presented our curriculum proposal to the chief of the Stanford Hospital Medicine Program. We identified her early in the process to be our primary mentor, and she proved instrumental in being an advocate. After several meetings with the hospitalist group to further develop our program, we presented it to the residency program leadership who helped us to finalize our program.
RESULTS
Needs Assessment
Twenty‐two out of 111 categorical residents in our program (19.8%) identified themselves as interested in hospital medicine and responded to the survey. There were several areas of a potential hospitalist curriculum that the residents identified as important (defined as 4 or 5 on a 5‐point Likert scale). These areas included mentorship (90.9% of residents; mean 4.6, standard deviation [SD] 0.7), opportunities to teach (86.3%; mean 4.4, SD 0.9), and the establishment of a formal hospitalist curriculum (85.7%; mean 4.2, SD 0.8). The residents also identified several rotations that would be beneficial (defined as a 4 or 5 on a 5‐point Likert scale). These included medicine consult/procedures team (95.5% of residents; mean 4.7, SD 0.6), point‐of‐care ultrasound diagnostics (90.8%; mean 4.7, SD 0.8), and a community hospitalist preceptorship (86.4%; mean 4.4, SD 1.0). The residents also identified several rotations deemed to be of lesser benefit. These rotations included inpatient neurology (only 27.3% of residents; mean 3.2, SD 0.8) and palliative care (50.0%; mean 3.5, SD 1.0).
The Final Product: A Hospitalist Training Curriculum
Based on the needs assessment and meetings with program leadership, we designed a hospitalist program and named it the Stanford Hospitalist Advanced Practice and Education (SHAPE) program. The program was based on 3 core principles: (1) clinical excellence: by training in hospitalist‐relevant clinical areas, (2) academic development: with required research, QI, and teaching, and (3) career mentorship.
Clinical Excellence By Training in Hospitalist‐Relevant Clinical Areas
The SHAPE curriculum builds off of our institution's current curriculum with additional required rotations to improve the resident's skillsets. These included ultrasound diagnostics, surgical comanagement, and QI (Box 1). Given that some hospitalists work in an open intensive care unit (ICU), we increased the amount of required ICU time to provide expanded procedural and critical care experiences. The residents also receive 10 seminars focused on hospital medicine, including patient safety, QI, and career development (Box 1).
Box
The Stanford Hospitalist Advanced Practice and Education (SHAPE) program curriculum. Members of the program are required to complete the requirements listed before the end of their third year. Note that the clinical rotations are spread over the 3 years of residency.
Stanford Hospitalist Advanced Practice and Education Required Clinical Rotations
- Medicine Consult (24 weeks)
- Critical Care (16 weeks)
- Ultrasound Diagnostics (2 weeks)
- Quality Improvement (4 weeks)
- Inpatient Neurology (2 weeks)
- Palliative Care (2 weeks)
- Surgical Comanagement (2 weeks)
Required Nonclinical Work
- Quality improvement, clinical or educational project with a presentation at an academic conference or manuscript submission in a peer‐reviewed journal
- Enrollment in the Stanford Faculty Development Center workshop on effective clinical teaching
- Attendance at the hospitalist lecture series (10 lectures): patient safety, hospital efficiency, fundamentals of perioperative medicine, healthcare structure and changing reimbursement patterns, patient handoff, career development, prevention of burnout, inpatient nutrition, hospitalist research, and lean modeling in the hospital setting
Mentorship
- Each participant is matched with 3 hospitalist mentors in order to provide comprehensive career and personal mentorship
Academic Development With Required Research and Teaching
SHAPE program residents are required to develop a QI, education, or clinical research project before graduation. They are required to present their work at a hospitalist conference or submit to a peer‐reviewed journal. They are also encouraged to attend the Society of Hospital Medicine annual meeting for their own career development.
SHAPE program residents also have increased opportunities to improve their teaching skills. The residents are enrolled in a clinical teaching workshop. Furthermore, the residents are responsible for leading regular lectures regarding common inpatient conditions for first‐ and second‐year medical students enrolled in a transitions‐of‐care elective.
Career Mentorship
Each resident is paired with 3 faculty hospitalists who have different areas of expertise (ie, clinical teaching, surgical comanagement, QI). They individually meet on a quarterly basis to discuss their career development and research projects. The SHAPE program will also host an annual resume‐development and career workshop.
SHAPE Resident Characteristics
In its first year, 13 of 25 residents (52%) interested in hospital medicine enrolled in the program. The SHAPE residents were predominantly second‐year residents (11 residents, 84.6%).
Among the 12 residents who did not enroll, there were 7 seniors (58.3%) who would soon be graduating and would not be eligible.
DISCUSSION
The training needs of aspiring hospitalists are changing as the scope of hospital medicine has expanded.[6] Residency programs can facilitate this by implementing a hospitalist curriculum that augments training and provides focused mentorship.[13, 14] An emphasis on resident leadership within these programs ensures positive housestaff buy‐in and satisfaction.
There were several key lessons we learned while designing our curriculum because of our unique role as residents and curriculum founders. This included the early engagement of departmental leadership as mentors. They assisted us in integrating our program within the existing internal medicine residency and the selection of electives. It was also imperative to secure adequate buy‐in from the academic hospitalists at our institution, as they would be our primary source of faculty mentors and lecturers.
A second challenge was balancing curriculum requirements and ensuring adequate buy‐in from our residents. The residents had fewer electives over their second and third years. However, this was balanced by the fact that the residents were given first preference on historically desirable rotations at our institution (including ultrasound, medicine consult, and QI). Furthermore, we purposefully included current resident opinions when performing our needs assessment to ensure adequate buy‐in. Surprisingly, the residents found several key rotations to be of low importance in our needs assessment, such as palliative care and inpatient neurology. Although this may seem confounding, several of these rotations (ie, neurology and palliative care) are already required of all residents at our program. It may be that some residents feel comfortable in these areas based on their previous experiences. Alternatively, this result may represent a lack of knowledge on the residents' part of what skill sets are imperative for career hospitalists. [4, 6]
Finally, we recognize that our program was based on our local needs assessment. Other residency programs may already have similar curricula built into their rotation schedule. In those instances, a hospitalist curriculum that emphasizes scholarly advancement and mentorship may be more appropriate.
CONCLUSIONS AND FUTURE DIRECTIONS
At out institution, we have created a hospitalist program designed to train the next generation of hospitalists with improved clinical, research, and teaching skills. Our cohort of residents will be observed over the next year, and we will administer a follow‐up study to assess the effectiveness of the program.
Acknowledgements
The authors acknowledge Karina Delgado, program manager at Stanford's internal medicine residency, for providing data on recent graduate plans.
Disclosures: Andre Kumar, MD, and Andrea Smeraglio, MD, are cofirst authors. The authors report no conflicts of interest.
Hospital medicine has grown tremendously since its inception in the 1990s.[1, 2] This expansion has led to the firm establishment of hospitalists in medical education, quality improvement (QI), research, subspecialty comanagement, and administration.[3, 4, 5]
This growth has also created new challenges. The training needs for the next generation of hospitalists are changing given the expanded clinical duties expected of hospitalists.[6, 7, 8] Prior surveys have suggested that some graduates employed as hospitalists have reported feeling underprepared in the areas of surgical comanagement, neurology, geriatrics, palliative care, and navigating the interdisciplinary care system.[9, 10]
In keeping with national trends, the number of residents interested in hospital medicine at our institution has dramatically increased. As internal medicine residents interested in careers in hospitalist medicine, we felt that improving hospitalist training at our institution was imperative given the increasing scope of practice and job competitiveness.[11, 12] We therefore sought to design and implement a hospitalist curriculum within our residency. In this article, we describe the genesis of our program, our final product, and the challenges of creating a curriculum while being internal medicine residents.
METHODS
Needs Assessment
To improve hospitalist training at our institution, we first performed a needs assessment. We contacted recent hospitalist graduates and current faculty to identify aspects of their clinical duties that may have been underemphasized during their training. Next, we performed a literature search in PubMed using the combined terms of hospitalist, hospital medicine, residency, education, training gaps, or curriculum. Based on these efforts, we developed a resident survey that assessed their attitudes toward various components of a potential curriculum. The survey was sent to all categorical internal medicine residents at our institution in December 2014. The survey specified that the respondents only include those who were interested in careers in hospital medicine. Responses were measured using a 5‐point Likert scale (1 = least important to 5 = most important).
Curriculum Development
Our intention was to develop a well‐rounded program that utilized mentorship, research, and clinical experience to augment our learner's knowledge and skills for a successful, long‐term career in the increasingly competitive field of hospital medicine. When designing our curriculum, we accounted for our program's current rotational requirements and local culture. Several previously identified underemphasized areas within hospital medicine, such as palliative care and neurology, were already required rotations at our program.[3, 4, 5] Therefore, any proposed curricular changes would need to mold into program requirements while still providing a preparatory experience in hospital medicine beyond what our current rotations offered. We felt this could be accomplished by including rotations that could provide specific skills pertinent to hospital medicine, such as ultrasound diagnostics or QI.
| Rotation | Non‐SHAPE | SHAPE |
|---|---|---|
| ||
| ICU | At least 12 weeks | At least 16 weeks |
| Medical wards | At least 16 weeks | At least 16 weeks |
| Ultrasound diagnostics | Elective | Required |
| Quality improvement | Elective | Required |
| Surgical comanagement | Elective | Required |
| Medicine consult | Elective | Required |
| Neurology | Required | Required |
| Palliative care | Required | Required |
Meeting With Stakeholders
We presented our curriculum proposal to the chief of the Stanford Hospital Medicine Program. We identified her early in the process to be our primary mentor, and she proved instrumental in being an advocate. After several meetings with the hospitalist group to further develop our program, we presented it to the residency program leadership who helped us to finalize our program.
RESULTS
Needs Assessment
Twenty‐two out of 111 categorical residents in our program (19.8%) identified themselves as interested in hospital medicine and responded to the survey. There were several areas of a potential hospitalist curriculum that the residents identified as important (defined as 4 or 5 on a 5‐point Likert scale). These areas included mentorship (90.9% of residents; mean 4.6, standard deviation [SD] 0.7), opportunities to teach (86.3%; mean 4.4, SD 0.9), and the establishment of a formal hospitalist curriculum (85.7%; mean 4.2, SD 0.8). The residents also identified several rotations that would be beneficial (defined as a 4 or 5 on a 5‐point Likert scale). These included medicine consult/procedures team (95.5% of residents; mean 4.7, SD 0.6), point‐of‐care ultrasound diagnostics (90.8%; mean 4.7, SD 0.8), and a community hospitalist preceptorship (86.4%; mean 4.4, SD 1.0). The residents also identified several rotations deemed to be of lesser benefit. These rotations included inpatient neurology (only 27.3% of residents; mean 3.2, SD 0.8) and palliative care (50.0%; mean 3.5, SD 1.0).
The Final Product: A Hospitalist Training Curriculum
Based on the needs assessment and meetings with program leadership, we designed a hospitalist program and named it the Stanford Hospitalist Advanced Practice and Education (SHAPE) program. The program was based on 3 core principles: (1) clinical excellence: by training in hospitalist‐relevant clinical areas, (2) academic development: with required research, QI, and teaching, and (3) career mentorship.
Clinical Excellence By Training in Hospitalist‐Relevant Clinical Areas
The SHAPE curriculum builds off of our institution's current curriculum with additional required rotations to improve the resident's skillsets. These included ultrasound diagnostics, surgical comanagement, and QI (Box 1). Given that some hospitalists work in an open intensive care unit (ICU), we increased the amount of required ICU time to provide expanded procedural and critical care experiences. The residents also receive 10 seminars focused on hospital medicine, including patient safety, QI, and career development (Box 1).
Box
The Stanford Hospitalist Advanced Practice and Education (SHAPE) program curriculum. Members of the program are required to complete the requirements listed before the end of their third year. Note that the clinical rotations are spread over the 3 years of residency.
Stanford Hospitalist Advanced Practice and Education Required Clinical Rotations
- Medicine Consult (24 weeks)
- Critical Care (16 weeks)
- Ultrasound Diagnostics (2 weeks)
- Quality Improvement (4 weeks)
- Inpatient Neurology (2 weeks)
- Palliative Care (2 weeks)
- Surgical Comanagement (2 weeks)
Required Nonclinical Work
- Quality improvement, clinical or educational project with a presentation at an academic conference or manuscript submission in a peer‐reviewed journal
- Enrollment in the Stanford Faculty Development Center workshop on effective clinical teaching
- Attendance at the hospitalist lecture series (10 lectures): patient safety, hospital efficiency, fundamentals of perioperative medicine, healthcare structure and changing reimbursement patterns, patient handoff, career development, prevention of burnout, inpatient nutrition, hospitalist research, and lean modeling in the hospital setting
Mentorship
- Each participant is matched with 3 hospitalist mentors in order to provide comprehensive career and personal mentorship
Academic Development With Required Research and Teaching
SHAPE program residents are required to develop a QI, education, or clinical research project before graduation. They are required to present their work at a hospitalist conference or submit to a peer‐reviewed journal. They are also encouraged to attend the Society of Hospital Medicine annual meeting for their own career development.
SHAPE program residents also have increased opportunities to improve their teaching skills. The residents are enrolled in a clinical teaching workshop. Furthermore, the residents are responsible for leading regular lectures regarding common inpatient conditions for first‐ and second‐year medical students enrolled in a transitions‐of‐care elective.
Career Mentorship
Each resident is paired with 3 faculty hospitalists who have different areas of expertise (ie, clinical teaching, surgical comanagement, QI). They individually meet on a quarterly basis to discuss their career development and research projects. The SHAPE program will also host an annual resume‐development and career workshop.
SHAPE Resident Characteristics
In its first year, 13 of 25 residents (52%) interested in hospital medicine enrolled in the program. The SHAPE residents were predominantly second‐year residents (11 residents, 84.6%).
Among the 12 residents who did not enroll, there were 7 seniors (58.3%) who would soon be graduating and would not be eligible.
DISCUSSION
The training needs of aspiring hospitalists are changing as the scope of hospital medicine has expanded.[6] Residency programs can facilitate this by implementing a hospitalist curriculum that augments training and provides focused mentorship.[13, 14] An emphasis on resident leadership within these programs ensures positive housestaff buy‐in and satisfaction.
There were several key lessons we learned while designing our curriculum because of our unique role as residents and curriculum founders. This included the early engagement of departmental leadership as mentors. They assisted us in integrating our program within the existing internal medicine residency and the selection of electives. It was also imperative to secure adequate buy‐in from the academic hospitalists at our institution, as they would be our primary source of faculty mentors and lecturers.
A second challenge was balancing curriculum requirements and ensuring adequate buy‐in from our residents. The residents had fewer electives over their second and third years. However, this was balanced by the fact that the residents were given first preference on historically desirable rotations at our institution (including ultrasound, medicine consult, and QI). Furthermore, we purposefully included current resident opinions when performing our needs assessment to ensure adequate buy‐in. Surprisingly, the residents found several key rotations to be of low importance in our needs assessment, such as palliative care and inpatient neurology. Although this may seem confounding, several of these rotations (ie, neurology and palliative care) are already required of all residents at our program. It may be that some residents feel comfortable in these areas based on their previous experiences. Alternatively, this result may represent a lack of knowledge on the residents' part of what skill sets are imperative for career hospitalists. [4, 6]
Finally, we recognize that our program was based on our local needs assessment. Other residency programs may already have similar curricula built into their rotation schedule. In those instances, a hospitalist curriculum that emphasizes scholarly advancement and mentorship may be more appropriate.
CONCLUSIONS AND FUTURE DIRECTIONS
At out institution, we have created a hospitalist program designed to train the next generation of hospitalists with improved clinical, research, and teaching skills. Our cohort of residents will be observed over the next year, and we will administer a follow‐up study to assess the effectiveness of the program.
Acknowledgements
The authors acknowledge Karina Delgado, program manager at Stanford's internal medicine residency, for providing data on recent graduate plans.
Disclosures: Andre Kumar, MD, and Andrea Smeraglio, MD, are cofirst authors. The authors report no conflicts of interest.
- . The hospitalist field turns 15: new opportunities and challenges. J Hosp Med. 2011;6(4):10–13.
- , , , , . The spectrum of community based hospitalist practice: A call to tailor internal medicine residency training. Arch Intern Med. 2007;167:727–729.
- , , , . Health care market trends and the evolution of hospitalist use and roles. J Gen Intern Med. 2005;20(2):101–107.
- , , , . Survey of the National Association of Inpatient Physicians. Ann Intern Med. 1999:343–349.
- , . Hospitalist educators: future of inpatient internal medicine training. Mt Sinai J Med. 2008;75(5):430–435.
- , , , , . Fulfilling the promise of hospital medicine: tailoring internal medicine training to address hospitalists' needs. J Gen Intern Med. 2008;23(7):1110–1115.
- , , , , . Closing the gap between internal medicine training and practice: recommendations from recent graduates. Am J Med. 2005;118(6):680–685
- , , , et al. Curricular content of internal medicine residency programs: a nationwide report. Am J Med. 2014;127(12):1247–1254.
- , , , . Hospitalists' perceptions of their residency training needs: results of a national survey. Am J Med. 2001;111(3):247–254.
- , , , et al. Reforming internal medicine residency training: a report from the Society of General Internal Medicine's Task Force for Residency Reform. J Gen Intern Med. 2005;20(12):1165–1172.
- , . Clinical hospital medicine fellowships: perspectives of employers, hospitalists, and medicine residents. J Hosp Med. 2008;3(1):28–34.
- , , , , , . Challenges and opportunities in academic hospital medicine: report from the Academic hospital medicine Summit. J Hosp Med. 2009;4(4):240–246.
- , , . Achieving hospital medicine's promise through internal medicine residency redesign. Mt Sinai J Med. 2008;75(5):436–441.
- , , , , . Training Future Hospitalists. Cult Med. 1999;171(12):367–370.
- . The hospitalist field turns 15: new opportunities and challenges. J Hosp Med. 2011;6(4):10–13.
- , , , , . The spectrum of community based hospitalist practice: A call to tailor internal medicine residency training. Arch Intern Med. 2007;167:727–729.
- , , , . Health care market trends and the evolution of hospitalist use and roles. J Gen Intern Med. 2005;20(2):101–107.
- , , , . Survey of the National Association of Inpatient Physicians. Ann Intern Med. 1999:343–349.
- , . Hospitalist educators: future of inpatient internal medicine training. Mt Sinai J Med. 2008;75(5):430–435.
- , , , , . Fulfilling the promise of hospital medicine: tailoring internal medicine training to address hospitalists' needs. J Gen Intern Med. 2008;23(7):1110–1115.
- , , , , . Closing the gap between internal medicine training and practice: recommendations from recent graduates. Am J Med. 2005;118(6):680–685
- , , , et al. Curricular content of internal medicine residency programs: a nationwide report. Am J Med. 2014;127(12):1247–1254.
- , , , . Hospitalists' perceptions of their residency training needs: results of a national survey. Am J Med. 2001;111(3):247–254.
- , , , et al. Reforming internal medicine residency training: a report from the Society of General Internal Medicine's Task Force for Residency Reform. J Gen Intern Med. 2005;20(12):1165–1172.
- , . Clinical hospital medicine fellowships: perspectives of employers, hospitalists, and medicine residents. J Hosp Med. 2008;3(1):28–34.
- , , , , , . Challenges and opportunities in academic hospital medicine: report from the Academic hospital medicine Summit. J Hosp Med. 2009;4(4):240–246.
- , , . Achieving hospital medicine's promise through internal medicine residency redesign. Mt Sinai J Med. 2008;75(5):436–441.
- , , , , . Training Future Hospitalists. Cult Med. 1999;171(12):367–370.